A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

ClinicalTrials.gov ID: NCT07218926

Public ClinicalTrials.gov record NCT07218926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

Study identification

NCT ID: NCT07218926
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 450 participants

Conditions and interventions

Conditions

Gastrointestinal Neoplasms

Interventions

IDRX-42 Drug
Sunitinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2, 2025
Primary completion: May 29, 2028
Completion: Nov 28, 2030
Last update posted: Apr 2, 2026

2025 – 2030

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
GSK Investigational Site	Phoenix	Arizona	85054	Recruiting
GSK Investigational Site	Jacksonville	Florida	41076	Recruiting
GSK Investigational Site	Orlando	Florida	32806	Recruiting
GSK Investigational Site	Iowa City	Iowa	52242	Recruiting
GSK Investigational Site	Overland Park	Kansas	66210	Recruiting
GSK Investigational Site	Boston	Massachusetts	02114-2696	Recruiting
GSK Investigational Site	Boston	Massachusetts	02215	Recruiting
GSK Investigational Site	Rochester	Minnesota	55905	Recruiting
GSK Investigational Site	Omaha	Nebraska	68130	Recruiting
GSK Investigational Site	Lake Success	New York	11042	Recruiting
GSK Investigational Site	New York	New York	10032	Recruiting
GSK Investigational Site	Durham	North Carolina	27710	Recruiting
GSK Investigational Site	Philadelphia	Pennsylvania	19106	Recruiting
GSK Investigational Site	Philadelphia	Pennsylvania	19111	Recruiting
GSK Investigational Site	Knoxville	Tennessee	37920	Recruiting
GSK Investigational Site	Dallas	Texas	75246	Recruiting
GSK Investigational Site	Houston	Texas	77030	Recruiting
GSK Investigational Site	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07218926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 2, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07218926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →